These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 18833104)

  • 1. [The therapeutic potential of cerebrolysin in the preventive therapy of Alzheimer's disease].
    Gavrilova SI; Fedorova IaB; Kolykhalov IV; Odinak MM; Emelin AIu; Kashin AV; Selezneva ND; Kalyn IaB; Roshchina IF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(8):24-8. PubMed ID: 18833104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Possibilities of preventive treatment of Alzheimer's disease: results of the 3-year open prospective comparative study on efficacy and safety of the course therapy with cerebrolysin and cavinton in elderly patients with the syndrome of mild cognitive impairment].
    Gavrilova SI; Kolykhalov IV; Fedorova IaB; Selezneva ND; Kalyn IaB; Roshchina IF; Odinak MM; Emelin AIu; Kashin AV; Gustov AV; Antipenko EA; Korshunova IuA; Davydova TA; Messler G
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(1):62-9. PubMed ID: 20436440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological approaches to the therapy of Alzheimer's disease].
    Gavrilova SI
    Vestn Ross Akad Med Nauk; 2006; (9-10):30-4. PubMed ID: 17111921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer's disease].
    Gavrilova SI; Kolykhalov IV; Korovaĭtseva GI; Zharikov GA; Kalyn IaB; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(4):27-34. PubMed ID: 15880838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia.
    Allegri RF; Guekht A
    Drugs Today (Barc); 2012 Apr; 48 Suppl A():25-41. PubMed ID: 22514793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Delayed effects of cerebrolysin in the prevention of cognitive impairment progression in the first degree relatives of patients with Alzheimer's disease: the role of the ApoE genotype].
    Selezneva ND; Gavrilova SI; Kolykhalov IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(10. Vyp. 2):31-38. PubMed ID: 33205928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neuropsychological evaluation of long-term therapy of Alzheimer's disease using different cerebrolysin dosages].
    Roshchina IF; Gavrilova SI; Zharikov GA; Kalyn IaB; Kolykhalov IV; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(1):52-5. PubMed ID: 15704485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The influence of cerebrolysin on the efficiency of subsequent therapy with amiridine++ in Alzheimer's disease patients (neuropsychological investigation)].
    Roshchina IF; Kolykhalov IV; Selezneva ND; Zharikov GA; Gerasimov NP; Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(12):43-6. PubMed ID: 10629930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognosis of cognitive deficit progression in aged patients with mild cognitive impairment under prolonged therapy (a three year observation)].
    Gavrilova SI; Kolykhalov IV; Fedorova IaB; Kalyn IaB; Selezneva ND; Samorodov AV; Miasoedov SN; Boksha IS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(3):45-53. PubMed ID: 23612410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of cerebrolysin on moderate cognitive impairment in cerebral vascular insufficiency (a clinical and electrophysiological study)].
    Damulin IV; Koberskaia NN; Mkhitarian EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(5):32-8. PubMed ID: 18379494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment and prevention of cognitive dysfunction in patients with arterial hypertension and atherosclerosis: results of a randomized double-blind placebo-controlled trial of cerebrolysin].
    Vereshchagin NV; Suslina ZA; Timerbaeva SL; Kashina EM; Gnezditskiĭ VV; Maksimova MIu; Rebrova OIu; Smirnova IN
    Ter Arkh; 2001; 73(4):22-7. PubMed ID: 11494441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cerebrolysin treatment of mild cognitive impairment of vascular genesis].
    Damulin IV; Mkhitarian EA; Koberskaia NN
    Ter Arkh; 2007; 79(6):65-9. PubMed ID: 17684971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An effect of long-term cerebrolysin therapy in combination with neuroleptics on behavioral and cognitive disturbances in endogenous childhood autism].
    Radzivil MG; Bashina VM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(2):21-5. PubMed ID: 16548370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.
    Panisset M; Gauthier S; Moessler H; Windisch M;
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1089-104. PubMed ID: 12111446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cerebrolysin Treatment Reduces the Risk of Mild Cognitive Decline to Dementia in 1st-Degree Relatives of Alzheimer's Patients: A Prospective Comparative Study].
    Selezneva ND; Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(8):90-97. PubMed ID: 37655416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.
    Alvarez XA; Cacabelos R; Laredo M; Couceiro V; Sampedro C; Varela M; Corzo L; Fernandez-Novoa L; Vargas M; Aleixandre M; Linares C; Granizo E; Muresanu D; Moessler H
    Eur J Neurol; 2006 Jan; 13(1):43-54. PubMed ID: 16420392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of cerebrolysin in the treatment of prolonged extrapyramidal complications of neuroleptic therapy].
    Kontsevoĭ VA; Medvedev AV; Andrusenko MP; Zvenigorodskaia IuV; Sheshenin VS
    Zh Nevrol Psikhiatr Im S S Korsakova; 1997; 97(6):39-44. PubMed ID: 11517474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials.
    Thome J; Doppler E
    Drugs Today (Barc); 2012 Apr; 48 Suppl A():63-9. PubMed ID: 22514795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with Cerebrolysin.
    Molloy DW; Standish TI
    J Neural Transm Suppl; 2000; 59():293-300. PubMed ID: 10961441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of prolonged therapy of vascular dementia].
    Klin Med (Mosk); 2011; 89(5):57-60. PubMed ID: 22242270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.